A new chromogranin A-dependent angiogenic switch activated by thrombin

Blood

Volumn 121, Issue 2, 2013, Pages 392-402

  Crippa, Luca ^a   Bianco, Mimma ^a   Colombo, Barbara ^a   Gasparri, Anna M ^a   Ferrero, Elisabetta ^a   Loh, Y Peng ^b   Curnis, Flavio ^a   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; THROMBIN;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANGIOGENIC SWITCH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CHEMICAL BOND; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRIN CLOT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RAT; STRUCTURE ACTIVITY RELATION;

EID: 84872327841     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-05-430314     Document Type: Article

References (48)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6(4):273-286. (Pubitemid 46505878)
2. Italiano JE Jr, Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008;111(3):1227-1233. (Pubitemid 351213404)
3. Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leuk Res. 2009;33(5):638-644.
4. Portela-Gomes GM, Grimelius L, Wilander E, Stridsberg M. Granins and granin-related peptides in neuroendocrine tumours. Regul Pept. 2010;165(1):12-20.
5. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci. 2007;64(22):2863-2886. (Pubitemid 351152248)
6. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348(12):1134-1149. (Pubitemid 36337325)
7. Veschini L, Crippa L, Dondossola E, Doglioni C, Corti A, Ferrero E. The vasostatin-1 fragment of chromogranin A preserves a quiescent phenotype in hypoxia-driven endothelial cells and regulates tumor neovascularization. FASEB J. 2011;25(11):3906-3914.
8. Theurl M, Schgoer W, Albrecht K, et al. The neuropeptide catestatin acts as a novel angiogenic cytokine via a basic fibroblast growth factor-dependent mechanism. Circ Res. 2010;107(11):1326-1335.
9. Ferrero E, Scabini S, Magni E, et al. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage. FASEB J. 2004;18(3):554-556.
10. Blois A, Srebro B, Mandalà M, Corti A, Helle KB, Serck-Hanssen G. The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells. Regul Pept. 2006;135(1-2):78-84. (Pubitemid 43816103)
11. Di Comite G, Rossi CM, Marinosci A, et al. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation. J Leukoc Biol. 2009;85(1):81-87.
12. Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A. Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy. Cancer Res. 2011;71(17):5881-5890.
13. Dondossola E, Crippa L, Colombo B, Ferrero E, Corti A. Chromogranin A Regulates Tumor Self-Seeding and Dissemination. Cancer Res. 2012;72(2):449-459.
14. Corti A. Chromogranin A and the tumor microenvironment. Cell Mol Neurobiol. 2010;30(8):1163-1170.
15. Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J. 2002;23(12):967-974. (Pubitemid 35203876)
16. Gregorc V, Spreafico A, Floriani I, et al. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer. Cancer. 2007;110(4):845-853. (Pubitemid 47257663)
17. O'Connor DT, Bernstein KN. Radioimmunoassay of chromogranin A in plasma as a measure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromocytoma. N Engl J Med. 1984;311(12):764-770. (Pubitemid 14026227)
18. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986;314(18):1145-1151. (Pubitemid 16138661)
19. Pieroni M, Corti A, Tota B, et al. Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J. 2007;28(9):1117-1127. (Pubitemid 47343865)
20. Corti A, Ferrari R, Ceconi C. Chromogranin A and tumor necrosis factor alpha in heart failure. Adv Exp Med Biol. 2000;482:351-359. (Pubitemid 32174544)
21. Zhang D, Lavaux T, Sapin R, et al. Serum concentration of chromogranin A at admission: an early biomarker of severity in critically ill patients. Ann Med. 2009;41(1):38-44.
22. Di Comite G, Previtali P, Rossi CM, et al. High blood levels of chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment. Ann Rheum Dis. 2009;68(2):293-295.
23. O'Connor DT, Mahata SK, Taupenot L, et al. Chromogranin A in human disease. Adv Exp Med Biol. 2000;482:377-388. (Pubitemid 32175148)
24. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol. 2004;39(10):969-973. (Pubitemid 39388461)
25. Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol. 1997;32(3):198-202. (Pubitemid 27105292)
26. Castoldi G, Antolini L, Bombardi C, et al. Oxidative stress biomarkers and chromogranin A in uremic patients: effects of dialytic treatment. Clin Biochem. 2010;43(18):1387-1392.
27. Giusti M, Sidoti M, Augeri C, Rabitti C, Minuto F. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol. 2004;150(3):299-303. (Pubitemid 38443779)
28. Corti A, Longhi R, Gasparri A, Chen F, Pelagi M, Siccardi AG. Antigenic regions of human chromogranin A and their topographic relationships with structural/functional domains. Eur J Biochem. 1996;235(1-2):275-280. (Pubitemid 26045443)
29. Ratti S, Curnis F, Longhi R, et al. Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem. 2000;275(38):29257-29263. (Pubitemid 32043794)
30. Chung H, Corti A, Crippa L, Schneider F, Metz- Moutigue MH, Garnero P. Development of an immunoassay for the derived-peptide of chromogranin A, Vasostatin-I (1-76): assessment of severity in patients with sepsis. Biomarkers. 2012;17(5):430-434.
31. Ponce ML, Kleinmann HK. The chick chorioallantoic membrane as an in vivo angiogenesis model. Curr Protoc Cell Biol. 2003;Ch 19:unit 19.5.
32. Go RS, Owen WG. The rat aortic ring assay for in vitro study of angiogenesis. Methods Mol Med. 2003;85:59-64.
33. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans. 2002;30(2):173-177.
34. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11(2):109-119.
35. Mandalà M, Stridsberg M, Helle KB, Serck-Hanssen G. Endothelial handling of chromogranin A. Adv Exp Med Biol. 2000;482:167-178. (Pubitemid 32174529)
36. Ramella R, Boero O, Alloatti G, Angelone T, Levi R, Gallo MP. Vasostatin 1 activates eNOS in endothelial cells through a proteoglycan-dependent mechanism. J Cell Biochem. 2010;110(1):70-79.
37. Dondossola E, Gasparri A, Bachi A, et al. Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. Cell Mol Life Sci. 2010;67(12):2107-2118.
38. Blois A, Holmsen H, Martino G, Corti A, Metz-Boutigue MH, Helle KB. Interactions of chromogranin A-derived vasostatins and monolayers of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine. Regul Pept. 2006;134(1):30-37.
39. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62(21):6132-6140. (Pubitemid 35244462)
40. Belloni D, Scabini S, Foglieni C, et al. The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration. FASEB J. 2007;21(12):3052-3062. (Pubitemid 47565526)
41. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269(43):26988-26995. (Pubitemid 24332901)
42. Parmer RJ, Mahata M, Gong Y, et al. Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. J Clin Invest. 2000;106(7):907-915.
43. Jiang Q, Taupenot L, Mahata SK, et al. Proteolytic cleavage of chromogranin A (CgA) by plasmin: selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J Biol Chem. 2001;276(27):25022-25029.
44. Koshimizu H, Kim T, Cawley NX, Loh YP. Chromogranin A: a new proposal for trafficking, processing and induction of granule biogenesis. Regul Pept. 2010;160(1-3):153-159.
45. Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D. Intracellular and extracellular processing of chromogranin A: determination of cleavage sites. Eur J Biochem. 1993;217(1):247-257. (Pubitemid 23305293)
46. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer. 2002;2(7):521-528. (Pubitemid 37328933)
47. Garcia-Lopez MT, Gutierrez-Rodriguez M, Herranz R. Thrombin-activated receptors: promising targets for cancer therapy? Curr Med Chem. 2010;17(2):109-128.
48. Folkman J. Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg. 2007;42(1):1-11. (Pubitemid 46043358)